Announcements from major insurance companies and healthcare providers

Eli Lilly's Zepbound and Mounjaro Cut Diabetes Risk by 94% with Weekly Injections

Aug 20, 2024, 12:19 PM

Eli Lilly's weight-loss drug, Zepbound, has shown a significant reduction in the risk of developing type 2 diabetes in a long-term study. The three-year SURMOUNT-1 trial demonstrated that adults with pre-diabetes and obesity or overweight who took tirzepatide, the active ingredient in Zepbound, had a 94% lower risk of progressing to diabetes compared to those on a placebo. Additionally, patients on the highest dose of Zepbound experienced an average weight loss of 22.9% over 176 weeks. These findings bolster the case for the long-term use of Zepbound and Mounjaro in managing obesity and preventing diabetes. The study involved weekly injections of the medication.